Anticoagulant Therapy Part 1: Heparin

نویسنده

  • Jack Hirsh
چکیده

The Thrombotic Process and Its Complications Thrombi are composed of fibrin and blood cells and may form in any part of the cardiovascular system, including the veins, arteries, heart, and microcirculation. Because the relative proportions of cells and fibrin depend on hemodynamic factors, they differ in arterial and venous thrombi.12 Arterial thrombi form under conditions of high flow and are composed mainly of platelet aggregates bound together by thin fibrin strands.3-5 In contrast, venous thrombi form in areas of stasis and are composed mainly of red cells with a large amount of interspersed fibrin and relatively few platelets. Thrombi that form in regions of slow to moderate flow are composed of a mixture of red cells, platelets, and fibrin and are known as mixed platelet-fibrin thrombi.45 When a platelet-rich arterial thrombus becomes occlusive, stasis occurs and the thrombus can propagate as a red stasis thrombus. As thrombi age, they undergo progressive structural changes.6 Leukocytes are attracted by chemotactic factors released from aggregated platelets2 or proteolytic fragments of plasma proteins and become incorporated into the thrombi. The aggregated platelets swell and disintegrate and are gradually replaced by fibrin. Eventually the fibrin clot is digested by fibrinolytic enzymes released from endothelial cells and leukocytes or becomes organized by connective tissue. The complications of thrombosis are caused by the effects of local obstruction of the vessel, distant embolization of thrombotic material, or, less commonly, consumption of hemostatic elements by their participation in the thrombotic process. Arterial thrombi usually form either in regions of disturbed flow or at sites of rupture of atherosclerotic plaques. Plaque rupture exposes the thrombogenic subendothelium to platelets and coagulation proteins; it may also cause further narrowing due to hemorrhage into the plaque.7-1" Arterial thrombi may remain partially occlusive or they may embolize. Nonocclusive thrombi may become incorporated into the vessel wall and can accelerate the growth of atherosclerotic plaques.9"1213 When flow is slow, the degree of stenosis severe, or the thrombogenic stimulus intense, the thrombi may become totally occlusive. Arterial thrombi usually occur in association with preexisting vascular

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Heparin Resistance During and Post-Intravenous Nitroglycerin Infusion

      Nitroglycerin has been reported to reduce activated partial thromboplastin time (aPTT) values in patients treated with concurrent heparin and nitroglycerin. However, studies have yielded conflicting results. To determine whether intravenous nitroglycerin alters the anticoagulant effect of heparin, we prospectively evaluated twenty patients admitted for coronary angioplasty by measurin...

متن کامل

Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

This chapter about hemorrhagic complications of anticoagulant treatment is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Bleeding is the major complication of anticoagulant therapy. The criteria for defining the severity of bleeding varies considerably between studies, accounting in part for the variation in the rates of bleeding repo...

متن کامل

Hemorrhagic complications of anticoagulant treatment.

Bleeding is the major complication of anticoagulant therapy. The criteria for defining the severity of bleeding varied considerably between studies, accounting in part for the variation in the rates of bleeding reported. Since the last review, there have been several meta-analyses published on the rates of major bleeding in trials of anticoagulants for atrial fibrillation and ischemic heart dis...

متن کامل

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

This article about hemorrhagic complications of anticoagulant and thrombolytic treatment is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Bleeding is the major complication of anticoagulant and fibrinolytic therapy. The criteria for defining the severity of bleeding vary considerably between s...

متن کامل

Thrombosis of A Prosthetic Mitral Valve After Withdrawal of Phenprocoumon Therapy

Patients with prosthetic heart valves require lifelong oral anticoagulant therapy based on vitamin K antagonists. These patients may need interruption of their anticoagulant therapy if they have to undergo surgery. The clinical challenge is to identify patients who can safely undergo surgery while continuing their vitamin K antagonist treatment and those who have to take short-acting heparin as...

متن کامل

Anticoagulation for ST-segment elevation myocardial infarction.

Adjunctive anticoagulant therapy reduces the risk of recurrent infarction and death in patients with STsegment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy.1–5 Unfractionated heparin (UFH), the first anticoagulant evaluated for this indication,1 continues to be used because of its predominantly nonrenal clearance, short half-life, reversibility, and the familiarity of ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2005